Icon

WELIREG (nda215383)- (40MG)

BELZUTIFAN MERCK SHARP DOHME
40MG
No No
2034-Sep-05 2026-Aug-13
None None
None No
WELIREG is a hypoxia-inducible factor inhibitor indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
0 0 0
Total Other Developers 8
Drugs with Suitability No
40MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

GenUs Advanced Search




Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.